Chanelle Pharma announces €86m investment over next five years

pharmafile | October 12, 2018 | News story | Medical Communications Ireland, chanelle, generics, investment, research 

Chanelle Pharmaceuticals, one of the largest Irish-owned pharmaceutical companies in Ireland, have announced an €86 million investment programme over the next five years.

The spending programme will see Chanelle Pharma build an €11 million manufacturing facility in Galway and the creation of 350 new jobs.  The company also intends to channel €45 million towards research and development.

The multinational firm which has offices in the UK and research laboratories in Jordan and Ireland says that although the majority of the new jobs will be focused towards R&D roles will also include quality assurance, production and tabletting.

The company also noted that their current strategy is to create strong links with multinational pharma firms in order for them to sell Chanelle’s products under their brand names.

The company spokesman speaking at the CPhI conference in Madrid also brushed off concerns surrounding Brexit as he suggested that the UK’s exit from the EU would not affect the company’s overall strategy.

Louis Goss

Related Content


Moderna up investments to produce 3 billion COVID vaccine doses in 2022

Moderna have announced it is making new funding commitments to increase supply at its owned …

Leading pharmaceutical companies sued in US for conspiring to drive up generics prices

26 pharmaceutical companies are being sued by most US states for allegedly conspiring to reduce …


Trump signs deal with generics company Phlow Corp to help shift drug manufacturing to the US

The Trump administration will sign a $354 million deal with the generics company Phlow Corp …

Latest content